炎症性肠病中的生物标志物：诊断应采用哪些？
Biomarkers in IBD: What to Utilize for the Diagnosis?
作者信息
D'Incà Renata, Sturniolo Giulia
机构信息
Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, 35124 Padua, Italy.
Department of Women's and Children's Health, University of Padua, 35128 Padova, Italy.
出版信息
Diagnostics (Basel). 2023 Sep 13;13(18):2931. doi: 10.3390/diagnostics13182931.
Abstract
The role of biomarkers in the diagnosis of inflammatory bowel disease is not fully characterized. C-reactive protein has a short half-life and elevates quickly after the onset of an inflammatory process; the performance is better in Crohn's disease than in ulcerative colitis. Erythrocyte sedimentation rate is easy to determine, widely available, and cheap, but the long half-life, the influence of age, anemia, smoking, and drugs limit its usefulness. Fecal markers have good specificity, but suboptimal accuracy. Microbial antibodies and novel immunological markers show promise but need further evidence before entering clinical practice. Proteomic methods could represent the dawn of a new era of stool protein/peptide biomarker panels able to select patients at risk of inflammatory bowel disease.
摘要
生物标志物在炎症性肠病诊断中的作用尚未完全明确。C反应蛋白半衰期短，在炎症过程发作后迅速升高；在克罗恩病中的表现优于溃疡性结肠炎。红细胞沉降率易于测定、广泛可得且价格低廉，但半衰期长、受年龄、贫血、吸烟和药物影响，限制了其用途。粪便标志物具有良好的特异性，但准确性欠佳。微生物抗体和新型免疫标志物显示出前景，但在进入临床实践前还需要更多证据。蛋白质组学方法可能预示着一个新时代的到来，即能够筛选出炎症性肠病风险患者的粪便蛋白质/肽生物标志物组合。
相似文献
1
Biomarkers in IBD: What to Utilize for the Diagnosis?
Diagnostics (Basel). 2023 Sep 13;13(18):2931. doi: 10.3390/diagnostics13182931.
2
Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5.
3
[Role of biological markers in inflammatory bowel disease].
Gastroenterol Hepatol. 2007 Mar;30(3):117-29. doi: 10.1157/13100073.
4
Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease.
Inflamm Bowel Dis. 2001 Aug;7(3):192-201. doi: 10.1097/00054725-200108000-00003.
5
Diagnostic role and clinical correlates of anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases.
Dig Liver Dis. 2003 Dec;35(12):862-8. doi: 10.1016/j.dld.2003.07.001.
6
Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease.
Inflamm Bowel Dis. 2009 Feb;15(2):199-205. doi: 10.1002/ibd.20535.
7
New Insights into Inflammatory Bowel Diseases from Proteomic and Lipidomic Studies.
Proteomes. 2020 Aug 10;8(3):18. doi: 10.3390/proteomes8030018.
8
Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies.
Inflamm Bowel Dis. 2008 Jan;14(1):32-9. doi: 10.1002/ibd.20275.
9
Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease.
Inflamm Bowel Dis. 2023 Sep 1;29(9):1399-1408. doi: 10.1093/ibd/izac230.
10
A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis.
Arthritis Res Ther. 2017 Feb 2;19(1):21. doi: 10.1186/s13075-017-1223-2.
引用本文的文献
1
Antibodies against integrin αvβ6 have high diagnostic accuracy for ulcerative colitis.
Front Immunol. 2025 Aug 21;16:1641329. doi: 10.3389/fimmu.2025.1641329. eCollection 2025.
2
Gut Feeling: Biomarkers and Biosensors' Potential in Revolutionizing Inflammatory Bowel Disease (IBD) Diagnosis and Prognosis-A Comprehensive Review.
Biosensors (Basel). 2025 Aug 7;15(8):513. doi: 10.3390/bios15080513.
3
The clinical application value of the biomarkers based on autophagy screening in the diagnosis and monitoring of inflammatory bowel disease in pediatric patients.
Eur J Pediatr. 2025 Jun 9;184(7):405. doi: 10.1007/s00431-025-06213-6.
4
Elevated butyric acid and histamine in feces and serum as an indicator of onset of necrotic enteritis in broiler chickens.
Front Microbiol. 2025 May 9;16:1581309. doi: 10.3389/fmicb.2025.1581309. eCollection 2025.
5
Inflammatory Bowel Disease in Children: Current Diagnosis and Treatment Strategies.
Cureus. 2025 Feb 3;17(2):e78462. doi: 10.7759/cureus.78462. eCollection 2025 Feb.
6
Precision Medicine in Inflammatory Bowel Disease: A Spotlight on Emerging Molecular Biomarkers.
Biomedicines. 2024 Jul 8;12(7):1520. doi: 10.3390/biomedicines12071520.
7
Inflammatory Bowel Disease: A Comprehensive Analysis of Molecular Bases, Predictive Biomarkers, Diagnostic Methods, and Therapeutic Options.
Int J Mol Sci. 2024 Jun 27;25(13):7062. doi: 10.3390/ijms25137062.
8
Exploration and verification a 13-gene diagnostic framework for ulcerative colitis across multiple platforms via machine learning algorithms.
Sci Rep. 2024 Jul 1;14(1):15009. doi: 10.1038/s41598-024-65481-8.
9
Clinical Validity of Anti-Proteinase 3 Antibodies in Patients with Inflammatory Bowel Disease: A Short Meta-Analysis.
Diagnostics (Basel). 2023 Dec 16;13(24):3682. doi: 10.3390/diagnostics13243682.
10
Type 2 autoimmune pancreatitis associated with ulcerative colitis.
Front Immunol. 2023 Dec 6;14:1288390. doi: 10.3389/fimmu.2023.1288390. eCollection 2023.
本文引用的文献
1
The value of 7 peripheral blood serum ratios in diagnosis and prediction of disease activity of patients within inflammatory bowel disease individuals.
Front Med (Lausanne). 2023 Apr 5;10:1122005. doi: 10.3389/fmed.2023.1122005. eCollection 2023.
2
Positioning and Usefulness of Biomarkers in Inflammatory Bowel Disease.
Digestion. 2023;104(1):30-41. doi: 10.1159/000527846. Epub 2022 Nov 18.
3
Serological profiling of Crohn's disease and ulcerative colitis patients reveals anti-microbial antibody signatures.
World J Gastroenterol. 2022 Aug 14;28(30):4089-4101. doi: 10.3748/wjg.v28.i30.4089.
4
Proteomic Analysis Identifies Three Reliable Biomarkers of Intestinal Inflammation in the Stools of Patients With Inflammatory Bowel Disease.
J Crohns Colitis. 2023 Jan 27;17(1):92-102. doi: 10.1093/ecco-jcc/jjac110.
5
Diagnostic Utility of Non-invasive Tests for Inflammatory Bowel Disease: An Umbrella Review.
Front Med (Lausanne). 2022 Jul 11;9:920732. doi: 10.3389/fmed.2022.920732. eCollection 2022.
6
Measurement of Serum IgG Anti-Integrin αvβ6 Autoantibodies Is a Promising Tool in the Diagnosis of Ulcerative Colitis.
J Clin Med. 2022 Mar 28;11(7):1881. doi: 10.3390/jcm11071881.
7
Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease.
Front Nutr. 2022 Jan 21;8:818902. doi: 10.3389/fnut.2021.818902. eCollection 2021.
8
Role of Serum Proteinase 3 Antineutrophil Cytoplasmic Antibodies in the Diagnosis, Evaluation of Disease Severity, and Clinical Course of Ulcerative Colitis.
Gut Liver. 2022 Jan 15;16(1):92-100. doi: 10.5009/gnl210211.
9
Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease.
Inflamm Bowel Dis. 2021 Oct 18;27(10):1564-1575. doi: 10.1093/ibd/izab032.
10
Identification of an Anti-Integrin αvβ6 Autoantibody in Patients With Ulcerative Colitis.
Gastroenterology. 2021 Jun;160(7):2383-2394.e21. doi: 10.1053/j.gastro.2021.02.019. Epub 2021 Feb 12.
Zotero 插件